申请人:Japan Tobacco Inc.
公开号:EP0887340A1
公开(公告)日:1998-12-30
The compounds of the formula (I)
wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.
式 (I) 的化合物
其中各符号如说明书中所定义,其药学上可接受的盐及其制药用途。本发明的化合物(I)及其药学上可接受的盐选择性地作用于大麻素受体,特别是外周受体,对中枢系统的副作用较小,具有优越的免疫调节作用、抗炎作用、抗过敏作用和对肾炎的治疗作用。因此,它们可用作大麻素受体(特别是外周大麻素受体)激活剂和拮抗剂、免疫调节剂、自身免疫性疾病治疗剂、抗炎剂、抗过敏剂和肾炎治疗剂。